Skip to main content

OraSure Tech Value Stock - Dividend - Research Selection

OraSure Tech

ISIN: US68554V1089, WKN: 881351

Market price date: 13.01.2021
Market price: 12,58 USD




OraSure Tech Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2020
Cash flow
Net operating cash flow 9.804.000
Capital Expenditures -9.314.000
Free cash flow 490.000
Balance sheet
Total Equity 307.145.000
Liabilities & Shareholders equity 349.295.000
Income statement
Net income 16.656.000
Eps (diluted) 0,270
Diluted shares outstanding 61.688.900
Net sales/revenue 148.073.000

Fundamental ratios calculated on: 13-01-2021

Ratios
Key figures 13-01-2021
Cash flow
P/C 79,16
   
P/FC 1.583,77
Balance sheet
ROI4,77
ROE87,93
Income statement
P/E46,59
Div. Yield0,00%
P/B2,53
P/S5,24


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolOSUR
Market Capitalization774.812.608,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsHealth service
Raw Data SourceUS GAAP in Millionen USD
Stock Split1987-04-08,3.0000/1.0000
Internetwww.orasure.com


Description of the company

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV?1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, OMNIgene DISCOVER, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, GenoFIND, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physicians\' offices, commercial and industrial entities, retail pharmacies, mass merchandisers, and consumers. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.orasure.com